North America grabs major revenue share of the global portable ultrasound bladder scanner market

Invasive surgeries performed by urologists necessitate the need for advanced imaging systems that provide intricate details on infected organs & tissues, as well as the maturation of a disease.

Replacing the existing imaging devices with 3D portable ultrasound bladder has been proven to improve the efficiency of treating urinary disorders. Images derived from portable ultrasound bladder scanners are also safeguarding the health of patients by providing accurate topography of infected organs, mitigating the risks of clinical misinterpretation. A recent study conducted by Future Market Insights has projected that over 90% of the global revenues from sales of portable ultrasound bladder scanner will be accounted by 3D products.

Future Market Insights’ report, titled “Portable Ultrasound Bladder Scanners Market: Global Industry Analysis & Opportunity Assessment, 2016-2026,” delivers insights on key factors driving the growth of the portable ultrasound bladder scanner market. By the end of 2026, the global market for portable ultrasound bladder scanners is projected to incur a steady growth in terms of market value, rising from an estimated US$ 93.8 million in 2016 to US$ 170.6 million, exhibiting a 6.2% CAGR during the period. 

According to the report, prevalence of independent urology care centres, pathology labs, and diagnostic facilities in the world reduces the potential risks of business impedance due to inadequate distribution. Hospitals will continue to be the largest end-users of portable ultrasound bladder scanners, while diagnostic centres will account for about 15% share of global revenues during the forecast period.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-2008

Operational flexibility of ultrasound scanning technology, coupled with the benefits of handy devices that facilitate visualization mobility, will continue favouring the growth in global sales of portable ultrasound bladder scanners. Urologic patients are expected to opt for non-invasive bladder scanning procedures that deliver results in real-time and decimate the need for catheterization, which will, in turn, promote the sales of portable ultrasound bladder scanners, globally. Although, global leaders in manufacturing of pharmaceutical & medical devices are compelled to lower the high costs of portable ultrasound bladder scanners for increasing penetration in the global healthcare devices market. 

Leading Manufacturers of Portable Ultrasound Bladder Scanners

A well-established supply chain urges medical device manufacturers to extend their production capacity for portable ultrasound bladder scanners. Strategic collaboration such as Investor AB-owned Patricia Industries acquisition of Laborie Medical Technologies Inc. indicate the aggressive measures are being undertaken by players in the global portable ultrasound bladder scanners market to expand their presence. Companies such as C. R. Bard, Inc., GE Healthcare Inc., Sonostar Technologies Co., Limited, and SRS MEDICAL SYSTEMS Inc., have recently made the news for being a part of acquisitions in the global portable ultrasound bladder scanner market. Other leading manufacturers of portable ultrasound bladder scanners, profiled in the market, include, Verathon Inc., Echo Son SA, dBMEDx Inc., Caresono Technology Co. Ltd, and Signostics Inc. 

Global Portable Ultrasound Bladder Scanners Market: Regional Analysis

North America’s portable ultrasound bladder scanner market will account for more than 40% of the global revenues through 2026. The region’s dominance in the global portable ultrasound bladder scanner market is predicted to be attributed by increasing healthcare expenditure in the US. Besides, the portable ultrasound bladder scanners sold in Western Europe are also expected to prominently factor the growth in global revenues. Clinical research institutions based in several Western European countries will be attributing towards development of advanced ultrasound scanning devices for key market players, a majority of whom have expanded their businesses in Europe. 

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-2008

The portable ultrasound bladder scanner market in Western Europe is projected to expand at a 6.0% CAGR throughout the forecast period. Furthermore, the revenues attained from sales of portable ultrasound bladder scanners in Asia-Pacific excluding Japan (APEJ) region have been forecasted to reach US$ 26.4 million by the end of 2026, registering expansion at the highest CAGR – 6.7%. On the other hand, Japan’s portable ultrasound bladder scanner revenues are projected to reach US$ 14.5 million revenues, while Latin America, Eastern Europe and Middle East & Africa (MEA) are expected to incur nascent growth in their portable ultrasound bladder scanner markets through 2026. 

Government initiatives in cancer treatment to fuel growth of the global biopsy device market during the projected period

Key players focussing on strategic M&A for amplified market shares

Patients are increasingly preferring minimally invasive surgical procedures in order to avoid conventional surgical complications and side-effects, promoting sales of biopsy devices, leading to the growth of the biopsy devices globally. In addition to enabling the accurate diagnosis, a biopsy device assures minimal patient discomfort and trauma. This is identified to be a major factor impacting the popularity of biopsy, and biopsy device thereby.

Over the 10-year forecast period 2016-2026, the global biopsy device market is estimated to witness a moderate yet promising CAGR of 6.5%, according to Future MarketaInsights. In a recently published report titled “Global Biopsy Device Market: Global Industry Analysis and Opportunity Assessment, 2016–2026”, Future Market Insights analyses the market for biopsy device and offers key insights into the market condition for the aforementioned period. Valued at around US$ 1,397 Mn in 2016, the market will possibly attain the revenues beyond US$ 2,621 Mn by 2026-end.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-1192

Key Opportunities for Manufacturers and Suppliers, Grasped by Future Market Insights Research:

• Developing economies present lucrative, untapped markets for biopsy device.
• Growing adoption of hybrid imaging technology will underpin new growth opportunities.
• Following massive consumption by hospitals, demand for biopsy device from specific oncology centres and research institutes will prompt at multiple opportunities in near future.
• Surging demand for minimal invasive breast biopsy highlight lucrative opportunities that lie in the breast cancer sector.
• Increasing adoption of biopsy device by oncologists will generate several revenue generation opportunities in the disease monitoring sector.

Supported by increasing discretionary funding for cancer research, growing government expenditure for healthcare and favourable reimbursement scenario (especially in the U.S.) will collectively elevate the revenue sales of the global biopsy device market. Collaborations between various government and private companies, fuelled by increasing awareness about disease diagnosis and monitoring, will further elevate the market growth in near future.

M&A and Technological Upgrades Remain at the Forefront

A majority of key players in the global biopsy device market are currently focusing on providing innovative biopsy tests and technological upgrades. Mergers, acquisitions, and partnerships with diagnostic laboratories will help to strengthen their presence in the global market.  

Among the top companies, Becton, Dickinson and Company is concentrating on innovative, cost-effective product development, whereas Hologic, Inc. is targeting manufacture and sales of biopsy devices, especially for breast cancer surgeries. Other notable players include Boston Scientific Inc., C. R. Bard, Inc., B. Braun Melsungen AG, Cook Medical, INRAD Inc., and PLANMED OY.

Argon Medical, one of the promising new entrants, is expanding its product portfolio and collaborating with established players, whereas for Devicor Medical Products Inc., M&A remains the key strategy.

North America Retains the Most Lucrative Market, Developing Countries to Witness Impressive Growth over 2016-2026

North America will remain the dominant market, reaching nearly US$ 882 Mn by 2026 end, accounting for over 33% share of the market. Western Europe is expected to remain the second largest market for biopsy device, crossing a value of US$ 683 Mn by the end of 2026, capturing over 26% share of the market.

APEJ, with around 14% market value share in 2026, is likely to reach US$ 370.0 Mn by the end of forecast period. MEA will register the fastest CAGR of 7.3%, followed by APEJ and Latin America with the respective CAGRs of 7.1% and 6.5% over 2016-2026. North America, Europe, and Japan will see moderate growth over the forecast period.

Needles Continue to Drive Product Type Segment

By product type, needles will remain dominant with over 36% share of the market value in 2026, whereas guns will represent the second largest sub-segment with over 26% market value share in 2026. With growing significance of early diagnosis of breast biopsy, guidance system segment is estimated to gain around 222 BPS in its market share by 2026 over 2016. Stereostatic X-ray guided biopsy will drive the guidance system segment through to 2026. Reagents and kits will witness moderate consumption.

Medical Diagnostics Monopolise Application Segment

Based on application type, medical diagnostics will continue to hold a dominant share of over 61% by 2026 end, in terms of revenues. Scientific research, accounting for the rest, will witness an impressively growing CAGR of 6.9% over 2016-2026. This segment is expected to reach beyond US$ 1,008.0 Mn in 2026.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-1192

Hospitals Remain Largest End-use Consumer

By end-user, hospitals will continue to contribute nearly 50% share to the market value by 2026 end. This end-use segment will witness a robust CAGR of 8.2%. Diagnostic centres will account for over 23% in 2026 with a slight decline over 2016-2026, whereas specialised oncology centres are anticipated to expand at a CAGR of 6.1% during 2016-2026.

Flourishing Protein Research Landscape Underpins Demand for Western Blot

Constant research ongoing in the field of proteomics and rising prevalence of AIDS will collectively contribute to the demand for western blotting technique. The global western blotting market is expected to reach a value of US$ 551.0 Mn by 2016 end. Developing economies in Asia Pacific will remain the most lucrative markets for western blotting, whereas North America will continue to lead the market globally.

Surging incidences of AIDS will continue to affect sizeable populace worldwide. Being considered as the gold standard and confirmatory test for HIV diagnosis, western blotting will continue to gain demand. Moreover, a range of other applications in a number of verticals, such as life science research, diagnostics, agriculture, food and beverages, and others, will also fuel the demand for western blotting.  In addition to hiking funds for proteomics research, technological advancements and innovations in the field of drug development are also likely to foster the demand for western blotting technique.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-1050

Promising introduction of automated western blotting and imaging is expected to fuel the market growth further. The personalised medicines development trend is proliferating, strengthening the market. Rising collaborations between leading pharmaceuticals companies and research institutions, as well as increasing M&A activities among key market players are expected to favour the growth of the global western blotting market.

However, emerging economies will continue to face a challenge of insufficient funding for proteomics research, eventually hampering the western blotting market. Moreover, higher product prices and lower availability may also remain the long-term restraints to market growth. In addition to strict regulations and demand for high-efficiency procedures, widespread availability of alternative techniques will remain a major barrier to mass adoption.

By product, the reagents kits segment will remain dominant over electrophoresis blotting systems and transfer membranes. Reagent kits segment is likely to account for over 61% market share of the 2016 revenues; however, this segment may witness a slight decline post-2016. A higher growth rate will be registered by the electrophoresis blotting systems segment, which is projected to approach a value of US$ 153.5 Mn by 2016 end.  

Based on application, the market is classified into five key segments viz. agriculture, medical diagnostics, food and beverages, scientific research, and others. By end-use, pharmaceutical and biotech companies segment will retain dominance, whereas research institutions segment is expected to witness a higher growth rate, followed by diagnostic laboratories segment.

On the basis of region, North America will remain the leading market with over 34% market value share in 2016. Asia Pacific is anticipated to remain the most lucrative market with over US$ 122 Mn revenues by 2016 end. This growth will be primarily driven by the prominence of bio-clustres present in developing Asian countries, including China and India. Compared to North America’s Y-o-Y growth of 4.8%, APAC is expected to exhibit a higher Y-o-Y of 5.2% in 2017 over 2016.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-1050

Some of the key players in the global western blotting market are Thermo Fisher Scientific, GE Healthcare, Bio-Rad Laboratories, and Merck Millipore. Other notable companies are PerkinElmer Inc., EMD Millipore Corporation, Hoffmann-La Roche Ltd., Advansta, Inc., and Bio-Techne Corporation (ProteinSimple Inc.), LI-COR, Inc., and Danaher Corporation (Lumigen, Inc.).           

Long-term Outlook: Over 2016-2021, the global western blotting market is foreseen to expand at a CAGR of 5.4%.

Global Peripheral Intravenous Catheter Market Poised for Stable Growth, Safety IV Catheter to Gain Significant Demand

The global peripheral intravenous catheter market is expected to observe steady growth in 2016, reaching beyond US$ 3.8 Bn by 2016 end. Wide adoption of catheterisation techniques in patient examination, diagnosis, and treatment is anticipated to fuel the demand for PIVC. Rising disease prevalence will play a key role in driving the market growth. North America is likely to remain the largest market; Asia Pacific is expected to emerge at the fastest rate.

Soaring disease prevalence will remain a prominent factor driving the demand for catheterisation, in turn pushing the market for PIVC. Apart from its usage in drug administration, increasing adoption of peripheral intravenous catheter in body fluid collection during a patient’s physical examination, is also identified to be a key driver to market growth. Prevalence of infections and epidemics are expected to further spur the demand for catheters in hospitals, clinics, ambulatory surgical centres, home healthcare units, and other healthcare centres. In addition to constantly enhancing healthcare infrastructure, the healthcare spending of consumers is also on the rise, which will favour the market growth.  

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-2558

Technological advancements in PIVC will particularly hold a positive impact on sales, boosting the market. Peripheral intravenous catheter is considered superior to its other counterparts, which will continue to drive adoption as a preferred option over other catheter types, eventually supporting the sales of PIVC. Moreover, there have been rising efforts toward manufacturing peripheral intravenous catheter using non-irritant, user-friendly material. Moreover, manufacturers are targeting PIVC design improvisation to eliminate the associated complications. This is projected to be a major factor positively influencing the market growth.

A few qualitative and technological complications associated with material composition, design, and after-effects of PIVC are expected to continue affecting mass adoption. In addition, market growth may be restricted due to expensive prices of peripheral intravenous catheter, especially in emerging economies. Conventional PIVC sales can also witness a drop owing to certain stringent medical device regulations in some of the developing countries.

By product, short peripheral intravenous catheter segment will remain dominant over integrated/closed peripheral intravenous catheter segment. Short PIVC segment is further sub-segmented into ported PIVC and non-ported PIVC. While short PIVC segment is expected to register the largest market share of over 71% in 2016, integrated/closed PIVC segment will witness significant Y-o-Y growth of 8.2%. Among the two sub-segments of short PIVC, non-ported PIVC is likely to remain dominant over ported PIVC.

On the basis of technology, safety peripheral intravenous catheter will continue to gain higher traction than conventional PIVC.

Based on end-user, hospitals segment is likely to generate the maximum PIVC demand. Ambulatory surgical units will also record decent demand. Peripheral intravenous catheter will register maximum revenue sales in 2016 in hospitals, accounting for over 60% market share. Ambulatory surgical units will remain the second most lucrative PIVC end-user segment.

By region, North America is expected to continue the leading position with around 45% share of the entire market revenues in 2016. Europe will continue to be the second largest market for PIVC with a value of over US$ 1.0 Bn in 2016. Asia Pacific is anticipated to emerge as the fastest growing region. Compared to a 5.8% of Y-o-Y of North America, APAC will witness a stronger Y-o-Y growth in 2017 over 2016.

Some of the leading players in peripheral intravenous catheter market, include Becton Dickinson and Company, B. Braun Melsungen AG, Smith Medical, C. R. Bard, Inc., Vygon Group, Terumo Corporation, and Tangent Medical.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-2558

Long-term Outlook: Global peripheral intravenous catheter market is slated to reach the revenues worth US$ 5.22 Bn by 2021.

Asia Pacific will Pip North America to Become the Largest Gamma Knife Market

The global Gamma Knife market, valued at US$ 172 million in 2015, is projected to increase at over 9% CAGR through 2025, surpassing US$ 400 million in revenues. Growth will be strongest in the U.S., EU5, Japan, South Korea, China, and India. Elekta and Varian Medical Systems will remain dominant players in developed regions, whereas China-based Huiheng Medical, Inc. will consolidate its position in Asia Pacific. North America, currently the largest market for Gamma Knife, will be relegated to second spot owing to strong adoption of Gamma Knife equipment in Asia Pacific.

High Success Rate Boosting Adoption among End-users

Increasing preference toward non-invasive procedures has positively impacted the adoption of radiation therapy, with LINAC, Cyber Knife, and Gamma Knife gaining traction in the healthcare sector. Increasing preference for minimally-invasive surgeries, positive perception toward Gamma Knife, and high success rate are among the chief factors expected to boost adoption during the forecast period, 2015-2025. Rising per capita healthcare expenditure, emphasis on R&D, and medical tourism are also expected to support the growth of Gamma Knife market in the long run. Technological advancement that make Gamma Knife safer and more effective are also expected to increase its adoption among end-users during the forecast period. However, high cost continues to be a major challenge for widespread adoption and can limit its adoption in developing countries.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-589

Brain Metastasis will be the Largest Disease Indication Segment

Gamma Knife radiation therapy is used to treat a number of disease indications, including brain metastasis, cancer, AVM, and trigeminal neuralgia. Among these, use of Gamma Knife for treating brain metastasis will account for a significant percentage of global market revenues, followed by cancer and trigeminal neuralgia. Throughout the forecast period 2015-2025, brain metastasis will remain the largest disease indication segment for Gamma Knife market.

Asia Pacific will pip both North America and Europe to emerge as the largest market for Gamma Knife by 2025. Robust adoption of Gamma Knife equipment in Japan, South Korea, China, and India will continue to drive the growth of the market in Asia Pacific. The Asia Pacific Gamma Knife market is projected to at over 10% CAGR during the forecast period 2015-2025. North America and Europe will lose market share to Asia Pacific and collectively account for nearly 50% revenue share of the market by 2025.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-589

Elekta, Varian Medical Systems, and Huiheng Medical, Inc. – leading Gamma Knife equipment manufacturers, will continue to leverage its position through innovative product development and foray into new markets.     

Cancer Supportive Care Products Market Estimated to Experience a Hike in Growth by 2021

Rising prevalence of cancers and adverse effects cases during cancer treatment will remain the most prominent factor driving the demand for cancer supportive care products on a global level. FMI indicates steady growth prospects for the global cancer supportive care products market over 2016-2021. The market is likely to reach US$ 25.35 Bn in 2016. Erythropoietin stimulating agents will register the highest consumption. North America is expected to retain the largest market.

Growing prominence of cancers is anticipated to spur the demand for supportive care. In addition, rising incidences of side-effects of anti-cancer therapy and superior results of existing anti-cancer drugs will collectively propel consumption of cancer supportive care products globally. Awareness about the usage of supportive care in cancer treatment, especially in developing countries, will also be a key factor highlighting the growing popularity of cancer supportive care products. Government initiatives regarding improved healthcare infrastructure, rising R&D investments, and augmenting healthcare spending are identified to be the major factors positively impacting the market growth. Since the past few years, innovative drug development has been on the priority for leading manufacturers. This is predicted to be a booster to the demand for cancer supportive care products.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-2550

However, high costs and inadequate reimbursement policies will remain longstanding challenges to the market growth. Moreover, promising entry of biosimilar drugs and loss of generic drugs brand exclusivity may also detain the market post-2016.  

By drug class, the global cancer supportive care products market has eight key segments i.e. non-steroidal anti-inflammatory drugs, anti-infective, anti-emetics, monoclonal antibodies, erythropoietin stimulating agents, opioid analgesics, bisphosphonates, and granulocyte colony stimulating factors. Erythropoietin stimulating agents segment will continue to dominate with over 24% value share in 2016. Granulocyte colony stimulating factors will however be the second largest segment with almost 20% market share by 2016 end.

Based on disease indication, lung cancer will continue to dominate other segments, including melanoma, leukemia, breast cancer, liver cancer, prostate cancer, bladder cancer, ovarian cancer, and others. Breast cancer segment is likely to emerge at the highest growth rate. This growth is attributed to increasing cases of genetic inheritance, evolving lifestyle of women, and rising adoption of hormone replacement therapy.

On the basis of distribution channel, the market is classified into three key segments viz. hospital pharmacies, retail pharmacies, and compounding pharmacies.

By geography, North America will remain the key market with over 43% market value share, followed by Europe with around 20% share by 2016, in terms of revenues. However, APAC is expected to witness at the fastest growth rate, creating the most lucrative market.

The key players participating in the global cancer supportive care products marketplace, include Baxter International Inc, Novartis Ag., Johnson & Johnson, Amgen Inc., Hoffmann LA- Roche Ltd, APR Applied Pharma Science Research S.A., Teva Pharmaceuticals Industries Ltd, Fagron Group BV, Acacia Pharma Ltd., and Kyowa Hakko Kirin Co Ltd. Leading manufacturers are increasingly concentrating on developing new supportive care products to stand out from competition.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-2550

Long-term Outlook: Over 2016-2021, the global market for cancer supportive care products is poised to expand at a CAGR of around 4.5%, reaching a value of US$ 29.87 Bn by 2021 end.

Robust growth in skin treatment segment anticipated to drive the global radio frequency beauty equipment market in the next 10 years

Growing scepticism over invasive cosmetic procedures is diverting consumers towards radio frequency beauty treatments that deliver quick results through non-surgical equipment.

Soaring demand for radio frequency beauty equipment is growing on account of higher acceptance of emerging technologies that act as effective alternatives to conventional methods. Global production of radio frequency beauty equipment is anticipated to skyrocket since their demand has been ascending rampantly in both developed and developing markets. In North America, top-grossing industries such as fashion, film and television continue to necessitate the use of complex beauty equipment and devices for enhancing the consumer’s semblance. According to a recent study conducted by Future Market Insights, the radio frequency beauty equipment revenues in North America will account for over 35% revenue share of the market throughout the forecast period.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-1147

Future Market Insights’ report titled “Radio Frequency Beauty Equipment Market: Global Industry Analysis & Opportunity Assessment, 2016-2026” estimates that the global market for radio frequency beauty equipment, currently valued at US$ 154.6 million, will expand at a robust CAGR of 15.3% and garner US$ 643.9 million in revenues over the forecast period of 2016-2026. The report predicts that the radio frequency beauty equipment market in the Asia Pacific excluding Japan (APEJ) region will expand at the highest CAGR of 20.4%, while Japan will gain revenues worth US$ 40 million by the end of 2026.

Competitive Landscape

Catering to the rising demand for non-invasive beauty treatments, several medical device manufacturers have instated production of radio frequency beauty equipment on a large scale. Rectifying equipment-related complications arising during treatment procedures and reducing the volatile costs of manufacturing remains a top priority for key players in the global radio frequency beauty equipment market.

Cynosure Inc. and Lumenis are among the leading players collectively accounting for three-fourth revenue share of the global market. Strategic acquisitions and product launch are some common business strategies for Syneron Medical Ltd., Alma Lasers, and Valeant Pharmaceutical International, Inc. Other prominent players participating in the growth of the global radio frequency beauty equipment market include Cymedics, IBRAMED, Guangzhou Beautylife Electronic Technology Co. Ltd., and Dermeo.

Surging Demand for Portable Radio Frequency Beauty Equipment

A market share analysis on different types of products – table top devices, trolley mounted devices and portable devices – has estimated that trolley mounted devices will attain the highest value share of the global market for radio frequency beauty equipment through 2026. Nevertheless, trolley mounted radio frequency equipment is anticipated to incur a considerable dip over the forecast period and account for 49% of the market by 2026 end, which will be nearly 6% lesser than the present value share of the segment. While the value share of table top devices in the global market won’t be severely affected throughout the projection tenure, the demand for portable devices, on the other hand, is expected to soar at an impressive pace. By the end of 2026, revenues procured from global sales of portable radio frequency beauty devices are projected to surpass over US$ 135 million, registering increment at fastest CAGR of 19.1%.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-1147

Key Research Findings on Global Radio Frequency Beauty Equipment Market 

• Scars attained from invasive cosmetic surgeries are compelling consumers towards non-invasive procedures performed with radio frequency beauty equipment
• Skin treatment & body contouring – two prominent applications for radio frequency beauty equipment, will account for nearly 90% value share of the global market by 2026
• Based on technologies, equipment incorporating a combination of IPL and RF technologies will garner more demand, while the dominant segment of bipolar RF technology will rake in nearly US$ 200 million in revenue by the end of the forecast period
• Compared to home care settings, beauty care centres will go on to be the largest end-users of radio frequency beauty equipment in 2016 and beyond
• Serious complications arising from extensive exposure to radio frequency beauty equipment is raising concerns among market participants and end-users.

Sleep Apnea Diagnostic System Market Foreseen to Grow exponentially over 2026

Future Market Insights delivers key insights on the global sleep apnea diagnostic system market in its upcoming report titled “Sleep Apnea Diagnostic System Market: Global Industry Analysis and Opportunity Assessment, 2016–2026.”  The global sleep apnea diagnostic system market is estimated to exhibit a 7.3% CAGR by value during the assessed period, owing to numerous factors, about which Future Market Insights offers thorough insights and forecasts in this report.

Under the polysomnography devices, ambulatory PSG monitoring devices and clinical PSG monitoring devices are the two sub-segments that contribute to the polysomnography (PSG) devices. To provide in-depth insights on the pattern of demand defining the global sleep apnea diagnostic system market, the market is segmented into different types of end users. The home care settings segment is likely to witness a significant CAGR of 8.0% in the next 10 years in value terms. The actigraphy monitoring device product type segment is estimated to register a significant value CAGR of more than 8% during the forecast period.  

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-777

The factors powering demand for sleep apnea diagnostic systems are increasing healthcare expenditure on home care testing equipment and wearable devices. Increasing prevalence of obstructive sleep apnea is likely to lead to significant growth in cost incurred for treatment of sleep apnea, which is anticipated to create demand for more advanced devices for diagnosis of sleep apnea. Reimbursement companies adopt a more favorable policy towards HST over in-lab testing. Thus, rising demand for equipment and wearable devices used in HST testing is in turn expected to drive global sleep apnea diagnostic system market growth. Chronic snoring is a strong indicator of sleep apnea. Factors that can affect sleep quality include sleep biology, circadian rhythm, and shift work. Sleep can also be disturbed due to tension, depression and fatigue. These factors in turn are expected to positively impact the sleep apnea diagnostic system market during the projected period.

However, most patients suffering from sleep apnea do not know the difference between general sleeping disorders and normal snoring problems. Moreover, most patients are inclined towards symptomatic treatment. This is projected to inhibit the global sleep apnea diagnostic system market growth in the next few years.

Segmentation analysis

• Portable monitoring is used as an alternative test for obstructive sleep apnea as it is less expensive on account of its portability and requires less space. Also, it is quicker to initiate the process as compared to in-laboratory polysomnography testing. Owing to its usability as a device for ambulatory testing, the polysomnography segment is likely to witness moderate growth in the coming years.
• The home care settings segment is projected to witness robust growth due to better patient compliance as compared to the in-labs testing segment.

Regional analysis

Due to high obesity rates and improper lifestyles, the adoptability of sleep apnea services are higher in the North America region. Introduction of updated devices and owing to the simple and easy process of their regulatory approval, the market in North America is creating a positive impact on the global sleep apnea diagnostic system market.

This report assesses trends driving the growth of each segment of the global as well as regional markets and offers potential takeaways that could prove substantially useful to sleep apnea diagnostic system manufacturers looking to enter the global sleep apnea diagnostic system market. The North America market has been estimated to dominate the global sleep apnea diagnostic system market, accounting for maximum revenue share of the market by 2016 end. Collectively, North America and Western Europe markets are expected to account for approximately 66% revenue share of global sleep apnea diagnostic system market by 2016 end. Western Europe is projected to exhibit a significant CAGR of 7.4% between 2016 and 2026, followed by the Japan sleep apnea diagnostic systems market.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-777

Vendor insights

Some of the leading companies operating in the global sleep apnea diagnostic system market include SOMNOmedics GmbH, Dickinson and Company, Braebon Medical Corporation, Advanced Brain Monitoring, Inc.,  Becton, Natus Medical Incorporated, MGC Diagnostics Corporation, Cleveland Medical Devices Inc., Koninklijke Philips N.V.,BMC Medical Co, Ltd., and ResMed Inc.

Proteinase K Market to Witness Exponential Growth by 2026

Proteinase K is a million dollar market accounting for a small portion in reagents and enzymes. Proteinase K is mainly used in contract research organisations, biotechnology companies, academic institutes, and diagnostics laboratories. In terms of revenue, the global Proteinase K market is expected to reach US$ 33.4 Mn by the end of 2026, witnessing a CAGR of 6.1%.

A plethora of factors are expected to impact the growth of the global Proteinase K market. A significant rise in research and development activities, lesser production costs, broader application of Proteinase K and good product stability and specificity of Proteinase K will give a massive push to the revenue growth of the global Proteinase K market by the end of the forecast period. A steady rise of chronic diseases and better government backed investment channels to fund advanced research and development are expected to boost the expansion of the global Proteinase K market over the period of assessment. An increasing number of research activities, soaring expenditure on personal healthcare and increasing adoption of gene therapy has been significantly high in the U.S. market in the recent years, making North America the most lucrative regional market for Proteinase K.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-2399

Global Proteinase K Market: Segmental Forecast

• By form, the lyophilized powder form segment is anticipated to account for higher revenue share in the global Proteinase K as compared to the liquid form segment. Lyophilized powder from segment is expected to reach a market value of US$ 19.2 Mn by 2026, reflecting a CAGR of 6.3% over the forecast period. The growth in lyophilized powder form can be attributed to the increasing advantages of powder form over liquid form in case of storage and preservation of samples.
• By application, purification of DNA & RNA segment will account for the highest revenue share in the global Proteinase K market as compared to other applications of Proteinase K. Purification of DNA & RNA segment is expected to reach a value of US$ 19.2 Mn by 2026, reflecting a CAGR of 6.5% over the forecast period.
• By end user, the biotechnology companies segment is expected to project higher demand for Proteinase K as compared to other end user segments such as academic institutes and diagnostics laboratories. The strong growth in biotechnology companies can be attributed to an increasing use of Proteinase K in research and development and new drug discovery. The cost effectiveness of Proteinase K over other reagents is the key factor responsible for its increasing use in biotechnology companies. The biotechnology companies segment is expected to register the highest CAGR of 6.7% over the forecast period.

Global Proteinase K Market: Regional Market Projections

Demand for research in academics and funding facilities provided by the U.S government to support gene therapy and other activities for drug development is anticipated to boost the North America Proteinase K market. Followed by North America, Western Europe and APEJ are the most lucrative regions in the global Proteinase K market and are anticipated to grow by 5.7% and 6.1% respectively over the forecast period. Increasing demand for drug development, rising hereditary diseases due to changing lifestyles and growing disposable income are some of the factors expected to contribute to the growth of the global Proteinase K market. 

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-2399

Global Proteinase K Market: Vendor Insights

Top companies profiled in the global Proteinase K market report include Thermo Fisher Scientific Inc., Merck KGaA, Qiagen N.V., Worthington Biochemical Corporation, Sisco Research Laboratories Pvt. Ltd, Promega Corporation, Bioline and F. Hoffmann-La Roche AG among others. Leading market players are adopting different strategies such as product launches and acquisitions to maintain their market share. For instance, in November 2015, Merck KGaA acquired Sigma-Aldrich to strengthen and expand its consumable and reagent portfolio.

Paediatric Vaccine Market Foreseen to Grow exponentially over 2026

According to a new report published by Future Market Insights titled “Paediatric Vaccine Market: Global Industry Analysis & Opportunity Assessment, 2016 – 2026”, in terms of revenue, the global paediatric vaccine market is expected to increase at 12.2% CAGR during the forecast period 2016-2026. The global paediatric vaccine market is expected to reach US$ 27.97 Bn in 2016.

Paediatric vaccine market is a billion dollar market accounting for a substantial proportion of healthcare expenditure in the recent times. The paediatric vaccine market is segmented according to indication, technology and vaccine type. According to the indication, the paediatric vaccine market is sub segmented into pneumococcal, DTP, rotavirus, influenza, meningococcal, hepatitis B, Hib, MMR and polio. According to technology the market is further segmented into live or attenuated, inactivated or killed, toxoid, conjugate, subunit and recombinant vaccines. By vaccine type, the global paediatric vaccine market is segmented into monovalent and multivalent vaccines.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1317

A slew of routine immunisation initiatives rolled out by the government and private agencies has broadened the market for the paediatric vaccines. A new wave of funds pumped into the market by different government and private players to cork the rise of the child deaths across the globe has also opened a new window of opportunity for the paediatric vaccine market. As per the report of WHO (World Health Organization), the global spending on immunisation soared from US$21.4 to US$26.9 per infant in 2014. The massive economic boom in some regions of the world is expediting the growth of the paediatric vaccine market.

Segmentation analysis

• By indication, pneumococcal segment accounted for higher revenue share in global paediatric vaccines as compared to other product segments. The pneumococcal segment is expected to reach a value of US$ 31.58 Bn by 2026, reflecting a CAGR of 14.4% over the forecast period. The growth of pneumococcal segment is attributed to the increasing incidence of infectious diseases.

• In terms of revenue, Hib vaccine segment is the second most growing segment and is expected to reach a value of US$ 13.49 Bn by 2026, growing at a CAGR of 13.4%. Hepatitis B and meningococcal segment are expected to show double-digit CAGR growth in the forecast period contributing to the growth of global paediatric vaccine market.

• By technology, conjugate segment accounted for highest revenue share in global paediatric vaccine market as compared to live or attenuated segment. The conjugate segment is expected to reach a value of US$ 32.09 Bn by 2026, reflecting a CAGR of 14.8% over the forecast period. This is expected to be closely followed by the growth of pneumococcal and meningococcal vaccines in this segment

• By end user, institutional health centres account for higher demand for paediatric vaccine as compared to other end user segments such as hospital pharmacies and retail pharmacies. The strong growth in institutional health centres can be attributed to increasing government interventions in immunisation programs in order to improve vaccine coverage. Institutional health centres are expected to register highest CAGR of 13.8% over the forecast period.

Regional analysis

By region, North America is dominating the global paediatric vaccine market due to improved healthcare infrastructure in this region. The North America paediatric vaccine market is expected to be valued at US$ 20.15 Bn by 2026 growing at a CAGR for 11.0%. In addition to North America, demand for paediatric vaccines has been significantly growing in Western Europe and APEJ. APEJ is expected to grow at a CAGR for 14.9% over the forecast period and is expected to dominate the market by 2026 by generating revenue of US$ 22.69 Bn and revenues in Western Europe are anticipated to grow by 11.2%. Middle East and Africa is expected to grow at a CAGR of 12.6% and this growth is anticipated by growth government intervention for immunisation by carrying out national level immunisation campaigns and also disease specific immunisation campaigns.

Access Report with Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-1317

Vendor insights

Key players in the global paediatric vaccine market include Indian Immunologicals, GlaaxoSmithKline Plc., Pfizer Inc., Sanofi, Merck & Co. Inc., Panacea Biotec, Zydus Cadila, Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., and Bharat Biotech. The growth of paediatric vaccine market is attributed to the development in the research by key players in the field, for instance, in February 2016, GSK submitted US regulatory submission for expanding the indication of FLuLaval Quadrivalent, influenza vaccine, for infants more than 6 months. These developments will boost the growth of the global paediatric vaccine market.

Renal Biomarker Market to Witness Exponential Growth by 2026

Future Market Insights delivers key insights on the global renal biomarker market in a new report titled “Renal Biomarker Market: Global Industry Analysis and Opportunity Assessment, 2016–2026.” In terms of revenue, the global renal biomarker market is projected to register a healthy CAGR of 7.0% over the forecast period. In this report, Future Market Insights throws light on the various factors and trends impacting market growth over the forecast period (2016 – 2026).

Segmentation highlights

The global renal biomarker market is segmented on the basis of Biomarker Type (Functional Biomarker, Up-Regulated Proteins, Others); Diagnostic Technique (Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay, Liquid Chromatography-Mass Spectrometry); and End User (Diagnostic Labs,Outpatient Clinics, Research Centres, Hospitals).

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-1731

• The Functional Biomarker type segment is anticipated to be valued at US$ 471.2 Mn by the end of 2016, registering a CAGR of 7.6% over the forecast period. The Up-Regulated Proteins type segment is estimated to create absolute $ opportunity of US$ 19.5 Mn in 2017 over 2016
• The Enzyme Linked Immunosorbent Assay diagnostic technique segment is anticipated to witness high Y-o-Y rates of growth throughout the forecast period and is anticipated to reach a market valuation of US$ 390.9 Mn by the end of 2016. The Particle-Enhanced Turbidimetric Immunoassay diagnostic technique segment is estimated to register a CAGR of 7.0% over the forecast period
• The Diagnostic Labs end user segment is anticipated to reach a market value share of US$ 308.4 Mn by the end of 2016. The Outpatient Clinics end user segment is estimated to hold a market value share of 30.1% by the end of 2016, making it the second highest end user growth segment of the global renal biomarker market

Regional analysis

The global renal biomarker market is segmented into the seven key regions of North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan, and Middle East & Africa (MEA). The North America renal biomarker market is projected to witness high Yea-on-Year growth throughout the forecast period. The market in this region is anticipated to witness a CAGR of 7.6% over the forecast period. The presence of leading renal biomarker manufacturers and established distribution channels in North America is expected to create significant growth opportunities over the next 10 years. The Western Europe renal biomarker market is estimated to represent absolute $ opportunity of US$ 14.1 Mn in 2017 over 2016.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-1731

Vendor insights

The global renal biomarker market report profiles a few of the top companies dominating the global market. Leading market players featured in the report include Thermo Fisher Scientific Inc., BIOPORTO A/S, Abbott Laboratories, Astute Medical, Inc., Randox Laboratories Ltd. and Beckman Coulter, Inc. (Danaher Corporation). The report discusses individual strategies adopted by these companies in terms of enhancing product designing, creating new manufacturing facilities, market consolidation, and advanced R&D initiatives.

North America Outbound Medical Tourism Services Market to Observe Strong Development by 2026

According to a new report published by Future Market Insights titled “Outbound Medical Tourism Services Market: North America Industry Analysis and Opportunity Assessment, 2016–2026”, the North America outbound medical tourism services market is expected to reach a market valuation of US$ 15.53 Bn by 2016 end and this is likely to increase to US$ 150.36 Bn by 2026.

According to Future Market Insights, factors such as a large ageing baby boomer population, large uninsured population, and better technology and wider treatment options are expected to drive the revenue growth of the North America outbound medical tourism services market over the forecast period. Economic factors such as rising rate of health insurance premiums, high cost of medical treatments in the U.S., and parallel tourism with medical treatment are expected to boost the growth of the North America outbound medical tourism services market between 2016 and 2026.

The other factors impacting the North America outbound medical tourism services market are long waiting time for specialist appointments in the U.S. and increasing preference for non-conventional treatment options. The demand for cosmetic correction procedures and dental treatments has been significantly high in the U.S. market in recent years, making North America the most lucrative regional market for outbound medical tourism services. According to the International Society of Aesthetic Plastic Surgery, the U.S. was the largest market for cosmetic procedures in 2015.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-na-2158

Lack of effective follow-up care on returning home, rampant medical malpractices in medical tourism destinations, proliferation of superbugs in medical tourism destinations, problems associated with language barriers, and privacy concerns are some of the challenges anticipated to restrict revenue growth of the North America outbound medical tourism services market over the forecast period.

Segmentation highlights

The North America outbound medical tourism services market is segmented into the following therapeutic applications – Cosmetic Surgery Treatment, Dental Treatment, Cardiovascular Treatment, Orthopaedic Treatment, Cancer Treatment, Fertility Treatment, Weight Loss Treatment, Spinal Surgery Treatment, Neurology Treatment, and Other General Treatment.

• The Cosmetic Surgery Treatment segment is estimated to be valued at US$ 3,760.9 Mn by 2016 end
• The Cancer Treatment segment is anticipated to register a CAGR of 22.0% over the forecast period
• The Orthopaedic Treatment segment is estimated to create absolute $ opportunity of US$ 1,658.9 Mn in 2017 over 2016

Regional forecast

The North America outbound medical tourism services market is segmented into the two top countries of U.S and Canada. U.S. is projected to occupy a major share in the North America outbound medical tourism services market in terms of value. The U.S market is anticipated to be valued at US$ 14.98 Bn by the end of 2016. In terms of value, U.S. is expected to be the dominant regional market by 2026 end and is expected to register a CAGR of 25.7% over the forecast period. Canada is expected to have comparatively less market potential for outbound medical tourism services, registering a CAGR of 18.1% over the forecast period.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-na-2158

Vendor insights

The report profiles some of the top companies operating in the North America outbound medical tourism services market. Leading market players featured in the report are Apollo Hospital Enterprise Limited, Bumrungrad International Hospital, KPJ Healthcare Berhad, Christus Muguerza Hospital, WorldMed Assist, Mednamaste, and Global Medical Tourism Inc. Major market players are adopting strategies such as market expansion and strategic alliances to maintain their market share. Some of these companies are also adopting strategies such as backward integration to support their core business of medical tourism. Companies are offering services such as insurance and financing for medical tourism and are looking to expand their global footprint by enhancing their foreign customer base.